RedHill Biopharma (RDHL) Change in Cash (2012 - 2023)

RedHill Biopharma (RDHL) has reported Change in Cash for 12 consecutive years, with -$10.6 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Change in Cash fell 479.8% year-over-year to -$10.6 million in Q2 2023; TTM through Jun 2023 was -$20.0 million, a 107.99% decrease from a year earlier, with the FY2025 full-year figure at -$644000.0, up 32.99% from the prior year.
• Change in Cash was -$10.6 million for Q2 2023 at RedHill Biopharma, down from -$2.4 million in the prior quarter.
• Over five years, Change in Cash peaked at $280.9 million in Q4 2021 and troughed at -$59.4 million in Q2 2020.
• A 5-year average of $14.0 million and a median of -$1.2 million in 2022 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 8997.67% in 2021, down 821.02% in 2021.
• Over 5 years, Change in Cash stood at $17.3 million in 2019, then plunged by 82.19% to $3.1 million in 2020, then soared by 8997.67% to $280.9 million in 2021, then sank by 98.3% to $4.8 million in 2022, then plunged by 321.61% to -$10.6 million in 2023.
• The last three Change in Cash figures came in at -$10.6 million (Q2 2023), -$2.4 million (Q1 2023), and $4.8 million (Q4 2022), per Business Quant data.